Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Shield To File ST10 Oral Iron-Deficiency Drug After Strong Phase III Data

This article was originally published in The Pink Sheet Daily

Executive Summary

Shield Therapeutics will use robust Phase III data for its oral iron-deficiency therapy ST10 to seek marketing approval in Europe in the second half of 2014 for iron-deficiency anemia in inflammatory bowel disease, and then a subsequent NDA submission in the U.S. for treating iron-deficiency anemia in pre-dialysis patients with chronic kidney disease.

You may also be interested in...

Switzerland's Shield Therapeutics Raises $12M To Conduct Phase III Trials On Oral Iron Deficiency Product

Oral iron deficiency therapy to advance into Phase III this year on the back of $12 million fund raising for Swiss minnow, Shield Therapeutics.

Patient-Centric: Evotec’s CSO Explains R&D Strategy

Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.

Novo Nordisk, Evotec Link Around Chronic Kidney Disease

Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts